Article
Surgery
G. E. Wensink, Karen Bolhuis, Marloes A. G. Elferink, Remond J. A. Fijneman, Onno Kranenburg, Inne H. M. Borel Rinkes, Miriam Koopman, Rutger-Jan Swijnenburg, Geraldine R. Vink, Jeroen Hagendoorn, Cornelis J. A. Punt, Jeanine M. L. Roodhart, Sjoerd G. Elias
Summary: A prediction model for early extrahepatic recurrence (EHR) after local treatment of colorectal liver metastases (CRLMs) has been developed, which can predict 6-month EHR using routine clinical information and assist in clinical decision-making.
BRITISH JOURNAL OF SURGERY
(2023)
Article
Surgery
Kosuke Kobayashi, Yosuke Inoue, Yuki Kitano, Shoki Sato, Atsushi Oba, Yoshihiro Ono, Takafumi Sato, Hiromichi Ito, Yoshihiro Mise, Akio Saiura, Yu Takahashi
Summary: A predictive model for conversion surgery was developed and the long-term outcomes of patients with technically unresectable colorectal liver metastases were evaluated. Patients who underwent conversion surgery had significantly higher median overall survival compared to those who did not. The predictive model for conversion surgery was constructed using several predictive factors. Patients were graded according to their scores, and those in Grade A had significantly better overall survival than Grade B and C patients.
Article
Oncology
Jiro Kimura, Kenta Sui, Takahiro Murokawa, Motoyasu Tabuchi, Shinya Sakamoto, Jun Iwata, Tatsuo Iiyama, Takehiro Okabayashi
Summary: It remains unclear which patients with recurrence after a second hepatectomy will benefit from a third hepatectomy. Factors such as tumor size and CA 19-9 level can affect long-term outcomes.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Gabriel D. Ivey, Fabian M. Johnston, Nilofer S. Azad, Eric S. Christenson, Kelly J. Lafaro, Christopher R. Shubert
Summary: Colorectal cancer is one of the most common types of cancer, and at least half of patients diagnosed with it will develop metastatic liver disease. Surgical resection of colorectal liver metastases is considered potentially curative, but it is underutilized despite the availability of various operative strategies. Differing views on resectability may contribute to this underutilization.
Article
Radiology, Nuclear Medicine & Medical Imaging
Tomoaki Yoh, Antoine Perrot, Aurelie Beaufrere, Christian Hobeika, Riccardo Sartoris, Valerie Paradis, Valerie Vilgrain, Olivier Soubrane, Francois Cauchy, Maxime Ronot
Summary: This study examined the relationship between liver surface nodularity (LSN), chemotherapy-associated liver injury (CALI), and clinically relevant post-hepatectomy liver failure (CR-PHLF) in patients undergoing hepatectomy for colorectal liver metastases (CLM). The findings suggest that LSN >= 2.5 is significantly associated with CR-PHLF, while the association between LSN and CALI is not significant. LSN >= 2.5 and future liver remnant (FLR) < 30% were identified as significant preoperative predictors of CR-PHLF.
EUROPEAN RADIOLOGY
(2021)
Article
Surgery
Patryk Kambakamba, Emir Hoti, Sinead Cremen, Felix Braun, Thomas Becker, Michael Linecker
Summary: With constant technical improvement in liver surgery and the advent of effective chemotherapy, the opinion towards colorectal liver metastases has shifted from being palliative to being considered for resection. This has led to successful wider application of surgery and a better overall survival rate in highly selected cases.
Article
Surgery
Heather A. Lillemoe, Guillaume Passot, Yoshikuni Kawaguchi, Mario DeBellis, Olivier Glehen, Yun Shin Chun, Ching-Wei D. Tzeng, Thomas A. Aloia, Jonathan Lopez, Jean-Nicolas Vauthey
Summary: The study found that RAS/TP53 co-mutation is associated with worse overall survival after concurrent resection of colorectal liver metastases and extrahepatic disease.
Article
Oncology
Kiyohiko Omichi, Yosuke Inoue, Yoshihiro Mise, Atsushi Oba, Yoshihiro Ono, Takafumi Sato, Hiromichi Ito, Yu Takahashi, Akio Saiura
Summary: The optimal surgical strategy for patients with multiple colorectal liver metastases remains unclear. This study compared the outcomes of one-step hepatectomy (OSH) and two-stage hepatectomy (TSH) in treating these patients. The results showed no significant difference in treatment outcomes between the two surgical approaches.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Davit L. Aghayan, Airazat M. Kazaryan, Vegar Johansen Dagenborg, Bard Rosok, Morten Wang Fagerland, Gudrun Maria Waaler Bjornelv, Ronny Kristiansen, Kjersti Flatmark, Asmund Avdem Fretland, Bjorn Edwin
Summary: In this randomized trial comparing laparoscopic and open liver surgery for patients with colorectal liver metastases, there was no significant difference in survival outcomes between the two treatment groups. However, variability in 5-year overall survival rates by up to about 10 percentage points was observed.
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Oncology
Shin Kobayashi, Shinichiro Takahashi, Shogo Nomura, Motohiro Kojima, Masashi Kudo, Motokazu Sugimoto, Masaru Konishi, Naoto Gotohda, Hiroya Taniguchi, Takayuki Yoshino
Summary: The study found that in patients with solitary resectable colorectal liver metastases (CRLM), the presence of BRAF V600E mutation (mBRAF) significantly reduces overall survival, even to the extent of being comparable to unresectable cases.
Article
Oncology
Andrew A. Gumbs, Eric Lorenz, Tzu-Jung Tsai, Lee Starker, Joe Flanagan, Andrea Benedetti Cacciaguerra, Ng Jing Yu, Melinda Bajul, Elie Chouillard, Roland Croner, Mohammad Abu Hilal
Summary: This study examined the short-term outcomes of minimally invasive liver resection for patients with colorectal liver metastases. The results suggest that laparoscopic and robotic approaches may have advantages over open hepatectomy in terms of blood loss, hospital stay, and morbidity rates.
Article
Oncology
Laurence Gau, Mathieu Ribeiro, Bruno Pereira, Karine Poirot, Aurelien Dupre, Denis Pezet, Johan Gagniere
Summary: This meta-analysis confirms that both overall survival (OS) and recurrence-free survival (RFS) are impaired following liver surgery for CRLM in BRAF-mutated patients. The risks of hepatic and extrahepatic recurrences are significantly higher in BRAF-mutated patients, who often have right-sided colon primary tumors, primary positive lymph nodes, and multiple CRLM.
Article
Surgery
Timothy J. Vreeland, Amelia T. Collings, Ahmad Ozair, Alexandra M. Adams, Rebecca Dirks, Bradley S. Kushner, Iswanto Sucandy, David Morrell, Jake Whiteside, Mohammed T. Ansari, Jordan Cloyd, Sean P. Cleary, Eugene Ceppa, Ahmed M. Abou-Setta, Adnan Alseidi, Ziad Awad, Subhashini Ayloo, Joseph Buell, Georgios Orthopoulos, William Richardson, Samer Sbayi, Go Wakabayashi, Horacio Asbun, Bethany J. Slater, Aurora D. Pryor, D. Rohan Jeyarajah
Summary: This study summarizes the evidence-based recommendations for the use of minimally invasive surgery (MIS) in the resection of colorectal liver metastases (CRLM). The panel suggests that MIS hepatectomy can be considered when it is deemed safe, feasible, and oncologically effective based on individual patient characteristics and surgeon's judgment.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Review
Oncology
Mario Serradilla-Martin, Jose Ramon Oliver-Guillen, Pablo Ruiz-Quijano, Ana Palomares-Cano, Roberto de la Plaza-llamas, Jose Manuel Ramia
Summary: A systematic review showed that resection of liver metastases with inferior vena cava infiltration is a safe and feasible surgical option, offering acceptable postoperative morbidity, mortality rates, and overall survival for patients who were previously considered unresectable.
Article
Oncology
Erik Schadde, Dirk J. Grunhagen, Cornelis Verhoef, Lucyna Krzywon, Peter Metrakos
Summary: Colorectal liver metastases (CRLM) affect over 50% of colorectal cancer patients and can be cured through resection, with chemotherapy improving survival rates. The decision for resectability is based on oncological, technical, and patient factors, with advancements in chemotherapy leading to more emphasis on technical resectability. Various strategies have been developed to overcome volume limitations for resection of CRLM.
SEMINARS IN CANCER BIOLOGY
(2021)